BEIJING, July 23, 2014 /PRNewswire/ — Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (“Beijing CDC”) to…
SINGAPORE, July 23, 2014 /PRNewswire/ — Traditional Chinese Medicine (TCM) already has an important role for agarwood where it is used to relieve spasms and pain, treat the digestive system, regulate the vital organs (heart, lungs, liver), and to lowe…
TOKYO, July 23, 2014 /PRNewswire/ — – Investment to Foster Early Biotech Start-ups -Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”), a fully-fledged oncology pharmaceutical company, announced on July 23 that the company will be investing US$30 mi…
PHILADELPHIA, July 22, 2014 /PRNewswire/ — The Intellectual Property and Science business of Thomson Reuters, the world’s leading provider of intelligent information for businesses and professionals, today announced Cortellis Clinical Trials Intelligence, its global clinical-drug-trial intelligence database, marked an industry-first milestone with the documentation of more than 180,000 clinical trials, thus providing pharmaceutical professionals with greater and quicker access to critical data and strategic insights to build stronger, more effective clinical trials . The solution—launched in August 2013—is part of the Cortellis suite, the premier source of life sciences intelligence information and analytics across multiple disciplines including regulatory, business development, discovery and pre-clinical.
Thomson Reuters Cortellis Clinical Trials Intelligence provides life science professionals access to information and analytics from more than 180,000 global clinical trials, including coverage of drugs, biologics, diagnostics, biomarkers and medical devices, supporting unparalleled outcome searching. Cortellis users can gain deeper scientific and competitive insights by connecting clinical trial data with drug pipelines, patents, pre-clinical insights and biomarkers on a single, unified platform, reducing time spent compiling and analyzing clinical information, and to ultimately construct better trials. The information can also be accessed through APIs embedded in a customer’s existing workflow or third party software applications.
“We are proud to have reached this significant industry milestone within the first year of releasing Cortellis Clinical Trials Intelligence,” said Jon Brett-Harris, managing director, Thomson Reuters IP & Science. “This rapid development is a reflection of our continued commitment to provide the best available information to support the pharmaceutical industry in driving successful clinical trials.”
Cortellis Clinical Trial Intelligence makes program planning and competitive research simpler and more efficient as the number of clinical trials in the database continues to grow. The solution also allows users to discover competitor strategies for specific patient segments, biomarker utilization, end points and novel insights into disease processes and to uncover vital connections by integrating their internal, proprietary data with the wide variety of reference information available through Cortellis.
Learn more about Cortellis Clinical Trials Intelligence and Cortellis. Follow Cortellis (@Cortellis) on Twitter for the latest news in drug discovery, development, regulatory, commercialization, forecast and generics intelligence.
LONDON, July 22, 2014 /PRNewswire/ — The need to contain hospital operational costs, improve workflow efficiency, and to provide better access to healthcare, has led to the integration of healthcare services. In turn, integrated systems have supported the development of innovative and patient-centric delivery models such as patient-centred medical homes and care-at-a-distance solutions. A strong information system infrastructure will further facilitate affordable, accountable and integrated delivery of services along the continuum of care.
New analysis from Frost & Sullivan, Technologies Enabling Home Medical Devices and Integrated Care Systems, finds that health information exchange (HIE) systems are a key technological driver of new healthcare models. HIE refers to the digitisation of health records to create a central data repository that will ensure continuity of care, data legacy and data-drive health analytics.
Ongoing and imminent changes to regulatory and legislative policies pertaining to healthcare delivery, such as incentivising electronic information sharing and mandating meaningful use of patient health data, will encourage the adoption of information systems like HIE in many countries.
“These changes are likely to have far-reaching consequences for healthcare delivery, particularly in predictive diagnosis and population health management,” said Technical Insights Research Analyst Bhargav Rajan. “Instead of functioning merely as workflow aids, information systems are likely to transform the very nature of healthcare planning and delivery, ushering in predictive analytics and coordinated care management.”
One challenge to the adoption of technological frameworks is the fragmentation of the healthcare market in several countries, causing interoperability issues. Healthcare providers are also unwilling to make the high initial investment required for these systems.
Technology providers need to design systems-agnostic solutions that can be used across technology platforms in order to allay client concerns about interoperability and compatibility. Healthcare providers too must gauge and understand the value information systems bring to their practice in effecting affordable, quality service in line with patient needs.
“A fully functional, integrated healthcare system is a product of innovations in technology, management and implementation,” noted Rajan. “Of these, a solid technological infrastructure, led by dynamic and interactive information systems, will be key in establishing home and integrated care systems.”
If you are interested in more information on this study, please email Anna Zanchi, Corporate Communications, at firstname.lastname@example.org
Technologies Enabling Home Medical Devices and Integrated Care Systems, a part of the Technical Insights subscription, provides a holistic analysis of the various component technologies in integrated healthcare systems. The study highlights key technologies and industry forces that enable integrated healthcare delivery, with the goal of aiding technology and service providers in identifying disruptive innovations opportunities in this space. Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
MOUNTAIN VIEW, Calif., July 22, 2014 /PRNewswire/ — Based on its recent analysis of the magnetic resonance imaging (MRI) market, Frost & Sullivan recognizes Siemens Healthcare with the 2014 North American Award for Product Leadership. Siemens Healthcare’s FREEZEit solution, which employs Siemens’ MAGNETOM Aera and Skyra scanners, addresses the need for robust and motion-insensitive imaging. The solution’s sophistication and utility in patient care has boosted the evolution of body MRI imaging in the U.S. market.
“Currently, body MR imaging, which is the imaging of the chest, abdomen and pelvis, represents about 10 percent of the MR imaging procedure volume; yet some institutions have experienced a tripling of body referrals within a few years,” said Frost & Sullivan Principal Analyst Nadim Daher. “One of the reasons for their growth was the delivery of rapid, consistent exams that patients could complete even with limited breath-holding capabilities.”
Conventional MR imaging is sensitive to motion, whether voluntary (respiratory motion or physical movement by the patient) or involuntary (cardiac motion, bowel motion). Body MR imaging also requires the patient to hold their breath in order to achieve diagnostic image quality; however, children, the elderly or very sick patients find it difficult to comply with the breath-hold commands. Traditional systems also need robust fat suppression to amplify the conspicuity of the vessels and lesions. Furthermore, contrast timing is vital for the characterization of lesions by these systems.
StarVIBE and TWIST-VIBE, the two components of FREEZEit, enable providers to overcome these challenges and expand their body MR referrals beyond computed tomography, the preferred modality up to this point. Referring physicians now have the opportunity to choose imaging modalities without radiation doses, especially in cases such as hemangiomas, focal nodular hyperplasia (FNH) and benign adenomas, which need repeat exams throughout the lifetime of the patient.
StarVIBE intelligently resists motion artifacts and, therefore, facilitates free-breathing 3D T1 exams. This will allow for much faster exams and fewer repeat scans, which, in turn, will enable providers to schedule patients for shorter slots, enhance the utilization rate of their equipment and, ultimately, increase their revenue.
Meanwhile, TWIST-VIBE provides dynamic liver imaging with high temporal and spatial resolution and full 4D coverage. It catches the precise point of the arterial phase when using contrast so that even almost invisible liver lesions can be detected. This technology has an immediate impact on treatment decisions, saving time and costs for caregivers and patients.
“Siemens realized MRI’s untapped potential in body applications and is truly acting as a driver of progress in the MRI market,” noted Daher. “Its innovations have had a significant impact on patient care and can potentially help healthcare providers improve their efficiency and lower their costs.”
The company has leveraged technology innovation, product excellence and quality of service to advance clinical and patient outcomes, while enhancing the overall value and cost-efficiency of care. In recognition, Frost & Sullivan is pleased to present the 2014 Product Leadership Award to Siemens Healthcare.
Each year, Frost & Sullivan presents this award to the company that has demonstrated innovation in product features and functionality that provides enhanced quality and higher value to customers. The award recognizes the rapid acceptance such innovation finds in the marketplace.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.
SHANGHAI, July 22, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will releas…